Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | GAA | P10253 | 3/20 | 0.97 |
| ▸ | POLB | P06746 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.97 |
| ▸ | PARP1 | P09874 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | GNRHR | P30968 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11835594 | 0.79 | MEN1 (0.64) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL8598047 | 0.79 | GAA (0.63) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL21894108 | 0.79 | MEN1 (0.63) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL9504942 | 0.79 | MEN1 (0.63) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL3968268 | 0.79 | MEN1 (0.63) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL30989189 | 0.79 | MEN1 (0.63) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL7087257 | 0.76 | MAPT (0.59) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL2369095 | 0.76 | PARP1 (1.00) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL3287778 | 0.75 | MEN1 (0.58) | MEN1KMT2AMAPTGAAPOLB | |
| SCHEMBL30291834 | 0.75 | MEN1 (0.58) | MEN1KMT2AMAPTGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-7160888-B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER LAMBERT COMPANY LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| EP-1660497-A1 | [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060106262-A1 | Electrooptic chromophores with large optical birefringence for applications at high speed and short wavelengths | OPTIMER PHOTONICS, INC. | 2006-05-18 | — | — | US | disclosed |
| WO-2005019215-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2005-02-24 | — | — | US | disclosed |
| EP-1185265-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1185265-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-13 | — | — | EP | disclosed |
| US-6300325-B1 | HETEROCYCLIC RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM CORPORATION | 2001-10-09 | — | — | US | disclosed |
| WO-2000076501-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0991406-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-12-13 | — | — | EP | disclosed |
| EP-0991406-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0863881-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998032439-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1997010219-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE IN THE PREVENTION AND/OR THE TREATMENT OF BONE DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043309-A1 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | DRD1, DRD2, DRD3 | MEN1 3394/4885KMT2A 1551/4885MAPT 2222/4885 |
| US-20060287309-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MEN1 3394/4885KMT2A 1551/4885MAPT 2222/4885 |
| US-20060287310-A1 | [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | DRD1, DRD2, DRD3 | MEN1 3394/4885KMT2A 1551/4885MAPT 2222/4885 |
| US-20060106262-A1 | Electrooptic chromophores with large optical birefringence for applications at high speed and short wavelengths | EYA2, CRY2, EYA3 | MEN1 1833/4885KMT2A 2469/4885MAPT 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.